Positive top line revisions while lowered NOI margin Borrowing terms should improve even with higher...
Estimates up on higher production and oil prices Q1 could mark a turning point Discounts USD 68/bbl...
NAVPS (SEK) flat q-o-q and up 55% y-o-y in Q1’22 Trading at 45% discount to NAVPS Fair value rang...
GM down due to high transportation costs… ...so we lower 2022e GP by 10% Trading at EV/EBIT 9x-5x o...
Organic sales +4.4% y-o-y, adj. EBIT margin 13.2% (11%) Positive EBIT revisions from raised profitab...
Adj. EBITA SEK 267m (+10% vs. Infront cons. 242m) Guides for -20% q-o-q growth in Integrated Solutio...
The Prostatype Genomics Board has proposed a SEK 22.
This morning, HANZA reported its Q1 2022 earnings. Below is our first impressions on the report.
Redeye estimates that Smart Eye’s ramp-up of revenues will be delayed by 1-2 quarters.
Redeye initiates coverage on defense tech powerhouse W5 Solutions, which has established a strategic...
Redeye revises its fair value range after taking a closer look at Q1, an eventful quarter which saw ...
Redeye’s estimates on group level were right on target this time.
Redeye retains its positive view of Binero while making minor forecast adjustments following its Q1’...
Sales +24% y-o-y, +5% vs. ABGSCe We lift ‘22e-‘23e EBIT by 12-13% 13x-12x ’22e-‘23e EV/EBIT, ~25% di...
Sales 2% below and GM of 51% vs ABGSC at 70% Reiterates 2022 outlook with GM of 69-70% Expect small ...
Etteplan reports Q1 results on May 5th. We remain on the cautious side due to the seen increase in s...
Urb-it stärker sin position på befintliga marknader.
Vården har ett stort behov av att på ett säkrare sätt kunna bedöma luftflödet till barnet och vi tro...
Redeye sees a Q1 report with impressive sales growth while margins were somewhat short of our expect...
Atria reported Q1 adjusted EBIT of EUR 2.3m versus Refinitiv consensus at EUR -0.
